<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38526214</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1080-6059</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Emerging infectious diseases</Title><ISOAbbreviation>Emerg Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Novel Oral Poliovirus Vaccine 2 Safety Evaluation during Nationwide Supplemental Immunization Activity, Uganda, 2022.</ArticleTitle><Pagination><StartPage>775</StartPage><EndPage>778</EndPage><MedlinePgn>775-778</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3201/eid3004.231361</ELocationID><Abstract><AbstractText>Given its enhanced genetic stability, novel oral poliovirus vaccine type 2 was deployed for type 2 poliovirus outbreak responses under World Health Organization Emergency Use Listing. We evaluated the safety profile of this vaccine. No safety signals were identified using a multipronged approach of passive and active surveillance.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tobolowsky</LastName><ForeName>Farrell A</ForeName><Initials>FA</Initials></Author><Author ValidYN="Y"><LastName>Nsubuga</LastName><ForeName>Fred</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Gilani</LastName><ForeName>Zunera</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Kisakye</LastName><ForeName>Annet</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Ndagije</LastName><ForeName>Helen</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Kyabayinze</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Gidudu</LastName><ForeName>Jane F</ForeName><Initials>JF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Emerg Infect Dis</MedlineTA><NlmUniqueID>9508155</NlmUniqueID><ISSNLinking>1080-6040</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014454" MajorTopicYN="N" Type="Geographic">Uganda</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Uganda</Keyword><Keyword MajorTopicYN="N">poliovirus</Keyword><Keyword MajorTopicYN="N">vaccine safety</Keyword><Keyword MajorTopicYN="N">vaccines</Keyword><Keyword MajorTopicYN="N">viruses</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>25</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>25</Day><Hour>9</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38526214</ArticleId><ArticleId IdType="pmc">PMC10977820</ArticleId><ArticleId IdType="doi">10.3201/eid3004.231361</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cooper LV, Bandyopadhyay AS, Gumede N, Mach O, Mkanda P, Ndoutabé M, et al. Risk factors for the spread of vaccine-derived type 2 polioviruses after global withdrawal of trivalent oral poliovirus vaccine and the effects of outbreak responses with monovalent vaccine: a retrospective analysis of surveillance data for 51 countries in Africa. Lancet Infect Dis. 2022;22:284–94. 10.1016/S1473-3099(21)00453-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00453-9</ArticleId><ArticleId IdType="pmc">PMC8799632</ArticleId><ArticleId IdType="pubmed">34648733</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray EJ, Cooper LV, Bandyopadhyay AS, Blake IM, Grassly NC. The origins and risk factors for serotype-2 vaccine-derived poliovirus (VDPV2) emergences in Africa during 2016–2019. J Infect Dis. 2023;228:80–8. 10.1093/infdis/jiad004</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiad004</ArticleId><ArticleId IdType="pmc">PMC10304761</ArticleId><ArticleId IdType="pubmed">36630295</ArticleId></ArticleIdList></Reference><Reference><Citation>Alleman MM, Jorba J, Greene SA, Diop OM, Iber J, Tallis G, et al. Update on vaccine-derived poliovirus outbreaks—worldwide, July 2019–February 2020. MMWR Morb Mortal Wkly Rep. 2020;69:489–95. 10.15585/mmwr.mm6916a1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6916a1</ArticleId><ArticleId IdType="pmc">PMC7188410</ArticleId><ArticleId IdType="pubmed">32324719</ArticleId></ArticleIdList></Reference><Reference><Citation>Alleman MM, Jorba J, Henderson E, Diop OM, Shaukat S, Traoré MA, et al. Update on vaccine-derived poliovirus outbreaks—worldwide, January 2020–June 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1691–9. 10.15585/mmwr.mm7049a1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7049a1</ArticleId><ArticleId IdType="pmc">PMC8659190</ArticleId><ArticleId IdType="pubmed">34882653</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigouette JP, Henderson E, Traoré MA, Wassilak SGF, Jorba J, Mahoney F, et al. Update on vaccine-derived poliovirus outbreaks—worldwide, January 2021–December 2022. MMWR Morb Mortal Wkly Rep. 2023;72:366–71. 10.15585/mmwr.mm7214a3</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7214a3</ArticleId><ArticleId IdType="pmc">PMC10078846</ArticleId><ArticleId IdType="pubmed">37022974</ArticleId></ArticleIdList></Reference><Reference><Citation>Macklin GR, Peak C, Eisenhawer M, Kurji F, Mach O, Konz J, et al.; nOPV2 Working Group. Enabling accelerated vaccine roll-out for Public Health Emergencies of International Concern (PHEICs): Novel Oral Polio Vaccine type 2 (nOPV2) experience. Vaccine. 2023;41(Suppl 1):A122–7. 10.1016/j.vaccine.2022.02.050</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.02.050</ArticleId><ArticleId IdType="pmc">PMC10109087</ArticleId><ArticleId IdType="pubmed">35307230</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P, De Coster I, Bandyopadhyay AS, Revets H, Withanage K, De Smedt P, et al. The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study. Lancet. 2019;394:148–58. 10.1016/S0140-6736(19)31279-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)31279-6</ArticleId><ArticleId IdType="pmc">PMC6626986</ArticleId><ArticleId IdType="pubmed">31174831</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaman K, Bandyopadhyay AS, Hoque M, Gast C, Yunus M, Jamil KM, et al. Evaluation of the safety, immunogenicity, and faecal shedding of novel oral polio vaccine type 2 in healthy newborn infants in Bangladesh: a randomised, controlled, phase 2 clinical trial. Lancet. 2023;401:131–9. 10.1016/S0140-6736(22)02397-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)02397-2</ArticleId><ArticleId IdType="pmc">PMC9860215</ArticleId><ArticleId IdType="pubmed">36495882</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative. Independent experts advise move to next use phase for novel oral polio vaccine type 2. 2021.  Oct 11 [cited 2023 Mar 7]. https://polioeradication.org/news-post/independent-experts-advise-transition-to-next-use-phase-for-novel-oral-polio-vaccine-type-2-nopv2/</Citation></Reference><Reference><Citation>Rowhani-Rahbar A, Klein NP, Dekker CL, Edwards KM, Marchant CD, Vellozzi C, et al.; Risk Interval Working Group of the Clinical Immunization Safety Assessment Network. Biologically plausible and evidence-based risk intervals in immunization safety research. Vaccine. 2012;31:271–7. 10.1016/j.vaccine.2012.07.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.07.024</ArticleId><ArticleId IdType="pubmed">22835735</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Adverse events following immunization (AEFI) [cited 2023 May 26]. https://iris.who.int/bitstream/handle/10665/191391/a87773_eng.pdf</Citation></Reference><Reference><Citation>World Health Organization. Causality assessment of an adverse event following immunization (‎AEFI)‎: user manual for the revised WHO classification, 2nd ed., 2019.  update [cited 2023 Apr 10]. https://iris.who.int/bitstream/handle/10665/340802/9789241516990-eng.pdf</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative. GACVS (Global Advisory Committee on Vaccine Safety) sub-committee on novel type 2 oral poliovirus vaccine (nOPV2) safety assessment of nOPV2 safety data. 2023.  Jan 24 [cited 2023 Oct 1]. https://polioeradication.org/wp-content/uploads/2023/03/GACVS-nOPV2-committee-meeting-20230124.pdf</Citation></Reference><Reference><Citation>World Health Organization. Safety profile of nOPV2 vaccine [cited 2024 Jan 10]. https://www.who.int/groups/global-advisory-committee-on-vaccine-safety/topics/poliovirus-vaccines</Citation></Reference><Reference><Citation>Rivera Mejía L, Peña Méndez L, Bandyopadhyay AS, Gast C, Mazara S, Rodriguez K, et al. Safety and immunogenicity of shorter interval schedules of the novel oral poliovirus vaccine type 2 in infants: a phase 3, randomised, controlled, non-inferiority study in the Dominican Republic. Lancet Infect Dis. 2023;S1473-3099(23)00519-4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10881405</ArticleId><ArticleId IdType="pubmed">38109921</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>